Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T
cells) is effective (anti-tumor activity) and safe in three different patient populations.
These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative
colon cancer and 3. patients with other MSI positive cancers.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins